Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Disc Medicine (IRON) stock in plain English

Free brief · no signupStart here
IRONPublished Nov 8, 2026
Disc Medicine Inc
Healthcare · Biotechnology
Develops investigational therapies for severe red blood cell disorders like porphyria and anemia. Evaluates candidate molecules in clinical trials to pursue future marketing approvals.
Assets:
Bitopertin assetPhase 2 candidate for treating porphyria
DISC-0974 assetClinical program for anemia in myelofibrosis
Watertown facilityOperational clinical headquarters in Massachusetts
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

79
OPS ScoreOperating finances
Latest quote
-2.40%$76.11
$3.47B
n/a
-

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 08, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was IRON. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Disc Medicine (IRON) do?

Disc Medicine Inc (IRON) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops investigational therapies for severe red blood cell disorders like porphyria and anemia. Evaluates candidate molecules in clinical trials to pursue future marketing approvals. Develops clinical-stage therapies targeting fundamental biological pathways of red blood cell production. It is worth $3.47B on the market.

Market cap
$3.47B
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 08, 2026

IRON’s flags, in plain English

Each flag is a number from Disc Medicine’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 08, 2026.

Stupid Cash

Can pay this year's bills 20.3 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 10% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Insiders Hold

Insiders own 26.7% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Heavily Shorted

24.4% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.

Questions about IRON

How big is Disc Medicine?

Disc Medicine’s market cap is $3.47B: what all of its shares are worth together at today’s price.

What could go wrong with IRON?

The company generates no commercial product sales and relies entirely on external capital to fund operations. That is one risk on Disc Medicine’s card. Its first risk flag is Heavily Shorted, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Disc Medicine’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. IRON’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card